Urch Publishing | Publication

Discovery R&D

Title

Opportunities in Drug Delivery

Sub title

Identifying hot technologies, companies and markets

Author

Dr Brian Minter

Publication date

September 2003

ISBN

0954112172

Pages

179

Price

pdf £400 | print £400

Summary

The formulation and delivery of drugs have played a crucial role in the development and commercialisation of pharmaceutical products during the last decade and none of the most commercially successful drugs have escaped the attention of companies wishing to improve convenience of their delivery to the patient. Drug delivery will play an increasingly important role in the next decade as more macromolecules including proteins, peptides and oligonucleotides find their way to the market.

Brief Scope of this report

Identifies new opportunities for drug delivery companies and provides a summary of the developments associated with new delivery systems for the top selling drugs and macromolecules.

Reviews developments in novel delivery of top-selling polypeptides and proteins, macromolecules, which have also traditionally presented significant problems in terms of delivery to the patient.With increased current interest in alternative systems to oral and parenteral drug delivery, the report describes novel systems used for inhaled (pulmonary) and nasal delivery of drugs as well novel oral systems, transdermal and depot parenteral systems.

Profiles of companies specialising in drug delivery have been included, which focus on their technology and how it is being applied to improve delivery of small and macromolecules.

Buy by the Slice

Chapter 1. Introduction and Scope of Report		pdf £23

Chapter 2. Novel Formulations of Top-Selling Non-Biological (Small-Molecule) Drugs		pdf £105

Chapter 3. Peptides		pdf £211

Chapter 4. Polypeptides and Proteins		pdf £136

Chapter 5. Oligonucleotides		pdf £53

Chapter 6. Pulmonary (Inhaled) Delivery		pdf £113

Chapter 7. Nasal Delivery		pdf £38

Chapter 8. Buccal Delivery		pdf £20

Chapter 9. Transdermal Delivery		pdf £30

Chapter 10. Pegylation		pdf £30

Chapter 11. Liposomes and Lipid Formulations		pdf £23

Chapter 12. Oral Delivery of Drugs		pdf £90

Chapter 13. Parenteral Delivery of Drugs		pdf £20

Chapter 14. Company Profiles		pdf £248

TABLE OF CONTENTS

Content

Marketing Brochure
View the marketing brochure (pdf) includes a full table of contents

Executive Summary
View the Executive Summary (pdf)

1: Introduction and Scope of Report

2: Novel Formulations of Top-Selling Non-Biological (Small-Molecule) Drugs

3: Peptides

Rationale for Developing Peptides as Drugs
Peptides in Clinical Trials
Peptides in Pre-clinical Research and Development

4: Polypeptides and Proteins

Human Growth Hormone (hGH)
Insulin

Inhaled Insulin
Other Formulations of Insulin

Proteins

Erythropoietin
Factor VIII
G-CSF (Growth Colony Stimulating Factor)
Interferon Alfa
Interferon Beta
Interleukin-2 (IL-2)
Miscellaneous Proteins

Miscellaneous Proteins and Polypeptides in Research and Development
Companies Specialising in Delivery of Peptides and Proteins

5: Oligonucleotides

6: Pulmonary (Inhaled) Delivery

Products in Research and Development Based on Pulmonary Delivery
Companies Specialising in the Development of Novel Pulmonary Devices and Formulations

7: Nasal Delivery

Products in Research and Development and Based on Nasal Delivery
Companies with Expertise in Nasal Delivery

8: Buccal Delivery

9: Transdermal Delivery

Transdermal Estradiol Formulations in Research and Development
Transdermal Testosterone Formulations in R&D
Companies Developing Novel Transdermal Formulation SystemsEvaluating the target company

10: Pegylation

Comapnies with Expertise in PEGylation

11: Liposomes and Lipid Formulations

12: Oral Delivery of Drugs

13: Parenteral Delivery of Drugs

14: Company Profiles

Acrux
Adprotech
Advancis Pharmaceutical
Aerogen
Alkermes
Alza
Andrx Pharmaceuticals
Antares Pharma
AP Pharma
Applied Pharma Research
Aradigm
Atrix Laboratories
Aventis Respiratory Technology
BattellePharma
Bentley Pharmaceuticals
Bespak
Biovail
Boehringer Ingelheim
Cardinal Health
Chienna
Chiesi
CIMA Laboratories
Columbia Laboratories
DepoMed
Diatos
Direct-Haler
DOR BioPharma
Durect
Elan
Emisphere Technologies
Enzon Pharmaceuticals
Epic Therapeutics
Epicept
Ethypharm
Eurand
FeRx
Flamel Technologies
Focus Inhalation
Generex Biotechnology
Hovione
Inex Pharmaceuticals
IVAX
Kosmos Pharma
Labopharm Macrochem
Meridica
ML Laboratories
Mundipharma
NanoCarrier
Nastech Pharmaceutical
Nektar Therapeutics
Neopharm
Nobex
NovaDel Pharmaceuticals
Novavax
Noven Pharmaceuticals
Octoplus
Omeros Medical Systems
Osmopharm
PARI
Penwest Pharmaceuticals
Polygene
Profile Respiratory Systems
PR Pharmaceuticals
Protarga
QuatRx
Regulon
Salus Therapeutics
Sheffield Pharmaceuticals
Skye Pharma
Spherics
Theratechnologies
Transave
Transdermal Technologies
Unigene Laboratories
Valentis
Watson Pharmaceuticals
West Pharmaceuticals
ZentRx

Appendix: Forumulations of Leading 150 Products

List of Tables

Table 2.1 Novel Formulations of Selected Pharmaceuticals in Development
Table 3.1 Peptides on the Market as Therapeutic Agents
Table 3.2 Peptides in Clinical Trials
Table 3.3 Indications of Peptides in Clinical Trials
Table 3.4 Peptides in Pre-clinical Research and Development
Table 4.1 Sales of Growth Hormone in 2001
Table 4.2 Novel Formulations of Human Growth Hormone in Research and Development
Table 4.3 Insulin Sales by Major Companies in 2001
Table 4.4 Novel Formulations of Insulin in Research and Development
Table 4.5 Selected Proteins, Including 2001 Sales
Table 4.6 New Formulations of Erythropoietin in Research and Development
Table 4.7 Formulations of G(M)CSF in Research and Development
Table 4.8 Formulations of Interferon Alfa in Clinical and Pre-clinical Trials
Table 4.9 Novel Formulations of Interferon Beta in Research and Development
Table 4.10 Miscellaneous Proteins and Polypeptides in Clinical and Pre-clinical Trials
Table 4.11 Companies Specialising in Peptide and Protein Delivery
Table 5.1 Oligonucleotides in Research and Development
Table 5.2 Companies with Technologies for Delivery of Oligonucleotides
Table 6.1 Major Products on the Market Using Pulmonary-delivery Devices
Table 6.2 Products in Research and Development Using Pulmonary Delivery
Table 6.3 Companies Specialising in the Development of Novel Inhalation Devices and Formulation Technology
Table 7.1 Commercial Products Using Nasal-delivery Devices
Table 7.2 New Products in Development Using Nasal-delivery Devices
Table 7.3 Companies with Expertise in Nasal Delivery
Table 8.1 Companies with Specialist Technology for Buccal-delivery Systems
Table 9.1 Novel Products in Research and Development Employing Transdermal- delivery Systems
Table 9.2 Selected Companies Specialising in Transdermal Delivery
Table 10.1 PEGylated Products in Research and Development
Table 10.2 Companies with Expertise in PEGylation
Table 11.1 Companies Developing Liposomal and Lipid-based Formulations
Table 12.1 Companies Specialising in Oral Formulation Technology
Table 13.1 Companies Specialising in Parenteral Formulation Technology

Discovery R&D

Dr Brian Minter is the Managing Director of Chembio, a consultancy in the fields of fine chemicals and pharmaceutical businesses. Dr Minter is an author of a number of commercial publications on Cancer Therapy, Drug Delivery Systems and Reformulation Strategies. Prior to Chembio, Dr Minter has worked as a research biochemist at Pfizer (UK), as scientific editor for Biochimica Biophysica Acta (Elsevier Scientific Publications) in The Netherlands and as marketing manager of fine chemical intermediates for drug active production at DSM and Solvay Pharmaceuticals as well as drug and medical device registration at this same company. Dr Minter lives in The Netherlands.